Mary Reid, MSPH, PhD Mary Reid, MSPH, PhD

Mary Reid

MSPH, PhD
Prevention
About Mary Reid

Biography:

Dr. Reid is the Director of Cancer Screening and Survivorship at Roswell Park Comprehensive Cancer Center and a key member of the Roswell Park team that is collaborating with Cuban scientists on Cimavax. She is also currently a Professor of Oncology in the Department of Medicine. As Director of Cancer Screening and Survivorship, Dr. Reid has worked to expand Roswell Park’s pioneering Lung Cancer Screening program and develop other cancer screening initiatives within the Institute, working with clinical departments to increase the colon and breast screening programs. Dr. Reid is also developing a comprehensive survivorship clinical and outreach program.

Prior to joining Roswell Park, she served as Assistant Professor in the Division of Epidemiology and Biostatistics, College of Public Health and Co-Director of the Cancer Prevention and Control Training Program at the Arizona Cancer Center in Tucson.

She has authored or co-authored more than 95 publications, serves as a regular reviewer for several cancer, nutrition and epidemiology journals and as a regular adhoc reviewer for several National Cancer Institute grant mechanisms.

Positions

Roswell Park Comprehensive Cancer Center
  • Director of Cancer Screening and Survivorship
  • Professor of Oncology
State University of New York at Buffalo
  • Research Associate Professor
  • Department of Social and Preventative Medicine, School of Public Health

Background

Education and Training:

  • PhD - Department of Epidemiology, School of Public Health, University of Arizona, Tucson, AZ
  • MSPH - Department of Epidemiology, Division of Public Health, University of Massachusetts, Amherst, MA
  • BSN - College of Nursing, Northeastern University, Boston, MA

Professional Memberships:

  • 2010 - DSMB, Center for Population Health and Health Disparities, OSU, Columbus, OH
  • 2010 - NLST-ACRIN Scientific Review for Use of Biospecimens
  • 2010 - ACCP Lung Cancer Guidelines III, Lung Cancer Chemoprevention Chapter
  • 2010 - NCCN Lung Screening Consensus Committee Member
  • 2010 - AACR Frontiers of Prevention Program Committee Member
  • 2009 - NCCN, Non-Small Cell Lung Cancer Database, Local PI
  • 2007 - International Association of the Study of Lung Cancer (IASLC), Member
  • 2007 - Mock Study Section Member, AARC Grant Writing Workshop for Associate Members, AACR, Los Angeles, CA
  • 2005 - CALGB Prevention Committee Member
  • 2000 - American Society of Preventive Oncology (ASPO), Member Founding Member for Steering Committee for Junior Members Career Development
  • 1998 - American Association for Cancer Research (AACR), Member
Research

Research Overview:

Dr. Reid’s research interests focus on the early detection and chemoprevention of lung and head and neck cancers, and the evaluation of genetic/epigenetic biomarkers of early lesions in high risk populations. Dr. Reid is active in steering the High Risk Lung Cancer Screening Clinic at Roswell Park, where high risk patients are screened with CT and a bronchoscopy that combines standard white light with autofluorescent imaging. She has experience with chemoprevention trials including wheat bran fiber, selenium. Currently, she directs two ongoing trials in lung cancer prevention at Roswell Park. One ongoing trial is testing a form of Vitamin D. Dr. Reid, in collaboration with Candace Johnson, PhD and Donald L. Trump, MD, has obtained NCI funding to conduct a phase I toxicity study and a randomized, placebo controlled phase II clinical trial to supplement high risk current and former smokers with confirmed premalignant lesions of the lung. In addition, Dr. Reid and Alex Adjei, MD, PhD, have received funding to use low doses of a therapeutic agent, erlotinib, in aerodigestive cancer survivors who are found to have premalignant lesions on screening. The patients will be given progressively lower doses of this agent to assess the effectiveness of treatment on genetic markers in the lung and to assess the level of toxicity at these low doses.

Dr. Reid is also heading an effort with the Dental and Head and Neck clinical team to screen high risk head and neck cancer patients with conventional white light and autofluorescent imaging. These screening efforts have led to the involvement in NCI-sponsored clinical chemoprevention trials using new agents for the prevention of progression of premalignant lesions. Dr. Reid is also involved in biomarkers studies of early oral lesions and the risk of progression to cancer.

Roswell Park Institutional Activities:

  • 12/2008 - Presenter, Touch Science Program. An outreach program to Greater Buffalo science teachers to provide information on careers for young people in cancer at Roswell Park.
  • 2003 - Scientific Review Committee
  • 2003 - Lung Disease Site Research Group, Co-Director
  • 2003 - Lung Disease Site Research Group, Advisory Committee
  • 2004 - Head and Neck Disease Site Research Group, Scientific Director
  • 2004-2006 - Epigenetics Research Group
  • 2005 - Alliance Development Grant Reviewer, Ad Hoc
  • 2006-2009 - IT Advisory Committee
  • 2006 - Quality Care Clinical Research Council
  • 2006 - Translational Research Tissue Support Resource (TRTSR) Committee
  • 5/2007 - Pharmacokinetics Advisory Committee
  • 7/2007 - Clinical Research Feasibility and Prioritization Review (CRPC) Committee
  • 2007 - Nursing Research Task Force
  • 6/2008-2009 - Co-Chair, IT Focus Group
  • 6/2008 - Biostatistics Steering Committee
  • 9/2008 - Program Co-Director, Lung Cancer Symposium 2008, Niagara-on-the-Lake, September 5-7, 2008.
  • 2008 - Prevention Steering Committee
  • 2009 - CCSG Steering Committee
  • 2009 - Director, Thoracic Product Line
  • 2009 - Tissue Utilization Committee
  • 2010 - NYS Cancer Center Leadership Committee, Roswell Park Representative
  • 2011 - Co-Chair, Scientific Review Committee
  • 2011 - Department of Medicine Faculty Mentoring & Development Task Force

Other Institutional Activities:

  • 1999-2000 - College of Public Health Phase I and II Implementation Committee on Educational, University of Arizona
  • 1999-2000 - College of Public Health Education Integration Committee, University of Arizona
  • 1999-2002 - Co-Director for R25 Cancer Prevention and Control Training Program involving the training of 4 pre- and 7 post-doctoral fellows, Arizona Cancer Center, Tucson AZ
  • 2008 - Consultant, PEITC Trial in Lung Cancer, University of Minnesota.

Peer Review Activities:

Journal Peer Review
  • 1999 - Cancer, Epidemiology, Biomarkers and Prevention (CEBP)
  • 2002 - Nutrition and Cancer
  • 2002 - Clinical Cancer Research
  • 2002 - Cancer Research
  • 2002 - American Journal of Clinical Nutrition
  • 2003 - Oncology
  • 2003 - Journal of Alternative and Complimentary Medicine
  • 2003 - Trace Elements in Biology and Medicine
  • 2006 - American Journal of Epidemiology
  • 2007 - Archives of Internal Medicine
  • 2007 - Annals of Epidemiology
  • 2008 - Advisory Board Member, Trace Elements in Biology and Medicine
  • 2008 - Cancer Prevention Research
  • 2008 - Journal of Thoracic Oncology
  • 2010 - Journal of Environmental Research and Public Health
  • 2010 - Familial Cancer Journal
Grant Review Committee Member

Ad Hoc

  • 2003-2006 - NCI Grant Reviewer, Subcommittee G- Education
  • 4/2003 - NCI Grant Reviewer, Subcommittee E: PO1 Programs
  • 6/2005 - NCI Grant Reviewer, Subcommittee E: PO1 Programs
  • 2005 - AVON- P30 Supplemental Grants for Breast Cancer Biomarker Studies, Special Review Panel
  • 2007 - NCI- SPORE Review Panel, Adhoc
  • 2007 - Institutional Alliance Grants, RPCI
  • 6/2008 - NCI- Grant Reviewer, Subcommittee E: PO1 Programs
  • 3/2011 - NCI- CCSG Grant Reviewer
  • 10/2011 - NCI- CCSG Grant Reviewer
Grant Review Committee Member

Appointed Member

  • 2006-2010 - NCI Grant Reviewer, Subcommittee G- Education, Permanent member

Educational Contributions:

Teaching
  • 2001 - Cancer Epidemiology Course, Smoking and Cancer: A Review of the Current Literature, University of Arizona, Tucson AZ.
  • 2001 - Epidemiology Seminar, Smoking Assessment Questionnaire Validation Using Plasma Cotinine Levels, University of Arizona, Tucson AZ.
  • 2003 - Cancer Epidemiology Course lecture on Clinical Trials and Aerodigestive Cancers, Social and Preventive Medicine, University at Buffalo.
  • 2003 - Nutritional Epidemiology Course lecture on Dietary Intervention Trials, SPM, University at Buffalo.
  • 2004 - Oncology for Scientists- The Burden of Cancer, September and Chemoprevention, March. RPCI.
  • 2005 - Cancer Prevention and Control lecture on Laboratory Methods in Molecular Epidemiology, RPCI.
  • 2006 - Cancer Prevention and Control Course- Lung Cancer Prevention, RPCI.
  • 2006 - Cancer Pathology Course- Biomarkers of Premalignant Lesions of the Lung.
  • 2007-2009 - Principles of Chemotherapy
  • 2010 - Scientific Ethics Training Course, RPCI.
  • 2010 - Cancer Prevention & Control Course; Epidemiology & Prevention of Aerodigestive Cancers
  • 2011 - Oncology for Scientists- The Burden of Cancer, September, RPCI
Undergraduate/Master’s Students
  • 2005 - Jennifer Frustino (MS Natural Sciences Program, RPCI), graduated May 2005. Project title: “Levels of p16 Expression in the Buccal Cells of Non-Cancer and Former Cancer Patients with Varying Levels of Risk”. Role: Primary Faculty Advisor.
  • 2005 - Julie Wojtaszczyk (MS Natural Sciences Program, RPCI), graduated August 2005. Project title: “Levels of Cyclin D1 Expression in the Buccal Cells of Non-Cancer and Former Cancer Patients with Varying Levels of Risk”. Role: Primary Faculty Advisor.
  • 2005 - Nathan Mahoney (MS Natural Sciences Program, RPCI), graduated May 2005. Project title: “Evaluation of the Toxicity of Selenium Supplementation in a Clinical Trial”. Role: Faculty Committee Member.
  • 2005 - Balazs Gerloczy, MD (Oncologic Surgical Pathology Fellowship), Committee member, completed fellowship May 2005. Project title: “Inflammatory Cytokine Gene Polymorphisms in Lung Cancer Patients”. Role: Faculty Committee Member.
  • 2007 - Rashsmi Pande, DDS (MS in Natural Sciences, RPCI), Graduated May 2007. Project title: “Significance of Signet Ring Cells in the Prognosis and Outcome of Colorectal Cancer Patients”. Role: Primary Faculty Advisor.
  • 2007 - Sandra Jacob, RN, BSN (NP student at Damen College, Amherst, NY), Graduated December 2007. Role: Faculty Committee Member.
  • 2007 - Soumya Ramananda, BS (MS student in Natural Sciences, RPCI, Graduated May 2008). Project Title: “Early Detection of Premalignant Lesions of the Oral Cavity with Autofluorescence”. Role: Primary Faculty Advisor.
  • 2008 - Patricia Zagst, BS (MS student in Natural Sciences, RPCI, Expected graduation- September 2008). Project Title: “FDA Regulations for Chemopreventive Agents: Considerations of Toxicity and Efficacy”. Role: Primary Faculty Advisor.
  • 2008 - Rachel Kermis, (High school student intern from Nardin Private School, graduated June 2008). Faculty mentor for project, “Identification of Risk Factors and HPV exposure in Base of Tongue Tumors”. Poster presentation at the AHNS Meeting, San Francisco, CA, July 2008.
  • 2008 - Jaclyn Orlando, (BS student from Buffalo State University, Graduated - December 2008). Mentor for final student project, “Incorporating Active Smoking Cessation Clinic in the Thoracic Program at RPCI”.
  • 2010 - Anne Marie Parise, (MS in Natural Sciences, RPCI; Graduated– June 2011). Project Title: Assessment of High Risk Lung Cancer patients perception of chemoprevention. Role: Primary Faculty Advisor.
  • 2010 - Christopher Wilcox, MS in Natural Sciences, RPCI; Graduated – September 2011). Project: Association of HPV presence in Head & Neck tumor outcomes. Role: Primary Faculty Advisor.
Dissertation Committees
  • 2007 - Ravi Menezes, PhD, Epidemiology, SPM, SUNYUB, Graduation May 2007. Role: Faculty Committee Member.
  • 2007 - Darryl Somayaji, MS, RN, CCRC (PhD student, College of Nursing, University of Utah). Dissertation topic: Negotiating participation to oncology clinical trials for African Americans: race, identity, power and barriers to health. Expected graduation - December 2011. Role: Faculty Committee Member.
  • 2007 - Luke Peppone, PhD, Epidemiology, SPM, SUNYUB, Graduated May 2007. Role: Faculty Committee Member.
  • 2008 - Ravi Menezes, Saxon Graham Award for Excellence in Epidemiology and Community Health
  • 2008 - Vijay Jayaprakash, MBBS, PhD, Epidemiology, SPM, SUNYUB, Graduated- December 2008. Role: Primary Faculty and Dissertation Advisor.
  • 2008 - Kanitsak Boonanantanasarn, DDS (PhD student in Oral Biology, SUNYUB. Graduation – June 2010, Role: Dissertation committee member.
  • 2009 - Chukwumere Nwogu, MD, Thoracic Surgery (PhD student in Epidemiology, Cancer Pathology and Prevention, Roswell Park Cancer Institute. Expected graduation - 2012. Role: Faculty Advisor and Dissertation Advisor).
  • 2009 - Jennifer Frustino, DDS, (PhD student in Epidemiology, Cancer Pathology and Prevention, Roswell Park Cancer Institute. Expected graduation - 2012. Role: Faculty Advisor and Dissertation Advisor).
  • 2010 - Ngozi Nwizu, DDS, (PhD student in Edipemiology, Cancer pathology and prevention, Roswell Park Cancer Institute. Expected graduation – 2013. Role: Dissertation Advisor).
Postdoctoral Trainees
  • 2008 - Mary Platek, R25 Postdoctoral Fellow, RPCI. Research program goals: To develop research investigating the role of nutrition and nutritional status on response to radiation and chemotherapy for head and neck cancer. Current position: Assistant Professor at NYU, NY, NY. Role: Primary Mentor
  • 2008 - Zahanira Peitri, R25 Postdoctoral Fellow, RPCI. Research program goals: To develop research into the association tes and radon, on lung cancer risk in the greater Buffalo metropolitan area. Role: Secondary Mentor.
  • 2010 - Jennifer Frustino, R25 Postdoctoral Fellow, RPCI. Research program goals: To access the diagnostic potential of autofluorescence in the oral cavity.

Grant Support:

Completed Grants
  • 7/96-6/99 - Project Coordinator (35%), A Study of Genetic Alterations and Recurrence in Colorectal Polyps Associated with Smoking, ADCRC (PI: DS Alberts, MD) (Total Costs: $442,021).
  • 7/98-7/02 - Co-Director (55%), R25 Cancer Prevention and Control training Grant, NCI (PI: JR Marshall, PhD) (Total Costs: $3,539,303).
  • 2/00-12/00 - Principal Investigator (5%), Selenium Levels Predict Adenoma Recurrence, Cancer Prevention and Control Research Award, Arizona Cancer Center Core Grant Supplement (Total Cost: $9,580).
  • 7/00-7/01 - Co-Investigator (10%) Colon Cancer Prevention Program Project, NCI (PI: David Alberts, MD) (Total Costs: $20,545,742).
  • 7/00-7/02 - Co-Investigator (10%), Watchful Waiting, NCI (PI: James Marshall, PhD) (Total Costs: $576,310).
  • 7/00-7/02 - Co-Investigator (10%), Negative Biopsy Phase III Trial of Selenium, NCI (PI: James Marshall, PhD) (Total Costs: $620,866).
  • 7/00-8/05 - Co-Investigator (10%), Nutritional Prevention of Cancer, NCI (PI: James Marshall, PhD) (Total Costs: $275,000).
  • 11/01-7/02 - Principal Investigator (15%), Lung Cancer Prevention with Selenium Supplementation, ADCRC (Total Costs: $390,113).
  • 4/04-3/09 - Co-Investigator (20%), Lung Cancer Molecular Markers by Sex: An Intergroup Study, NCI- RO1 (PI: Christine Ambrosone, PhD), Total Costs: $3,746,750. The major goals of this project are to investigate gender differences in lung cancer, by assessment of biomarkers in tissue and blood and risk factor data.
  • 7/05-8/07 - Co-Investigator (5%) Periodontal disease and the Incidence of Oral Cancer, NCI-R03 (PI: Mine Tezal, PhD) (Total Costs: $100,000).
  • 09/05-08/11 - Principal Investigator (20%), Calcitriol for Chemoprevention in Preinvasive Bronchial Epithelial Lesions, NCI- RO1. Total Costs: $2,400,000. To test the use of Vitamin D (Calcitriol) in the prevention of progression of preinvasive bronchial epithelial lesions in a high risk former smoker cohort.
  • 12/05-11/10 - Co-investigator (5%), Biomarkers for the Progression of Head and Neck SCC, NCI- RO1 (PI: Norma Nowak, PhD), Total Costs: $1,500,000. To assess genetic changes in a series in the carcinogenic transformation that contributes to the formation of head and neck squamous cell carcinomas.
  • 04/08-03/10 - Co-Investigator (5%), NCI-R03 (PI: H. Zhao). DNA repair capacity and risk of pre-malignant lesions in the lung epithelium. Total costs: $100,000. To investigate the repair capacity in patients with progressive and regression premalignant lesions in the lung.
Current Grants
  • 09/08-08/11 - Co-Director (10%), Cancer Prevention and Control Training Program, NCI-R25 CA114101 (Marshall). The major goal of this program is to training post-doctoral fellows training in a trandisciplinary, translational program in cancer prevention and control.
  • 11/06-12/11 Principal Investigator (15%), Stacey Scott ABRIEN Lung Cancer Registry, RPCI Alliance Funding, Total Costs: $1,000,000.
  • 06/09-05/13 - Principal Investigator (20%). A Phase I study of Erlotinib in Patients with premalignant lesions of the lung. Total Costs: $1,255,573. LOI to NCI Phase I/II Contract with Northwestern University. To evaluate multiple low doses of erlotinib for toxicity and efficacy in high risk aerodigestive cancer survivors.
  • 07/09-09/11 - Co-Investigator (5%). Development of Blood Based microRNA Profile as a Biomarker of Lung Cancer, NCI-RO3 (PI: Santosh Parnaik). Total Costs: $100,000. To utilize stored blood in lung cancer and high risk screening controls to identify a profile of microRNA markers that will serve as biomarkers for lung cancer.
  • 07/10-06/15 - Consultant (5%). The UCLA – Boston University Lung Cancer Biomarker Development Laboratory, NIH/NCI-U01 (PI: Avrum Spria, MD, MSc). LOI to Boston University. Total Costs: $355,858. The major goal of this program is to develop and characterize new biomarkers and assays for the early detection of lung cancer through airway mRNA/microRNA profiling and proteomic profiling of blood.
  • 09/11-09/16 - Co-Investigator/Consultant. Family Smoking Prevention and Tobacco Control Act National Longitudinal Study, NIDA/FDA (PI: Andrew Highland, MD). Total Costs: $4,402,474. The National Longitudinal Survey of Tobacco Use (NLSTU) will develop a cohort of nearly 38,000 adults and 7,000 adolescents who will provide baseline biospecimens and annual tobacco use survey data.
  • 10/11-10/16 - PI on Local Subcontract (5%), Detection of Early Lung Cancer Among Military Personnel (DECAMP)”, DOD (PI: Avi Spria, MD). Surveillance SCT and bronchoscopy in military centers and RPCI to identify biomarkers associated with lung nodules that progress to cancer.
  • 12/11-08/14 - PI on Local Subcontract (10%), Benzo[a]pyrene Metabolism: Phenotyping and Genotyping", NCI- R01 (PI: Stephen Hecht, PhD). Determining the metabolism of benzo[a]pyrene in current smokers by genotype in a high risk lung cancer cohort.
  • 12/11-11/12 - Principal Investigator (5%), Assessment of Genomic Damage in Oral Lesions, RPCI Alliance Funding, Total funding $48,084. During the multi-year progression from normal cell to cancer, numerous genomic alterations arise in events ranging from single base mutations to gains or losses of entire chromosomes, resulting in massive alteration in cellular physiology.
Pending Grants
  • 07/12-06/15 - Principal Investigator (5%), Whole Blood MicroRNAs as Biomarkers of Lung Cancer, Dept of the Army (USAMRAA) DOD (PI: Reid). The benefit of early lung cancer detection and limitations of current paradigms: Lung cancer is the most common cause of cancer-related mortality, accounting for an estimated 159,000 deaths in the United States in 2009.
  • 07/12-06/16 - Co-Principal Investigator on Local Subcontract (10%), Molecular Determinants of Invasive Progression of Premalignant Lung Lesions, NIH (PI: Avi Spira, MD). Site will oversee and track the collection of the clinical data corresponding to the lung biopsy samples at RPCI through DECAMP network.

Invited Scholarly Presentations:

National
  • 1999 - CPC Seminar Series, “Smoking and Adenomatous Polyp Characteristics: a Case-Case Analysis”, Arizona Cancer Center, April 7, 1999.
  • 2000 - CPC Seminar Series, “Lung Cancer and Selenium Supplementation”, Arizona Cancer Center, September 20, 2000.
  • 2001 - ASPO, “Reports of toxicity on long-term supranutritional selenium supplementation: an analysis of a clinical trial”, March 11-13, 2001, New York, NY.
  • 2001 - AACR, “Lung Cancer and Selenium Supplementation”, March 24-28, 2001. New Orleans, LA.
  • 2002 - Society for Epidemiologic Research (SER), “Biomarkers for Lung Cancer Chemoprevention”, June 21, 2002. Palm Springs, CA
  • 2003 - SELECT Trial Workshop for SWOG, “Reporting on the Nutritional Prevention of Cancer Trial”, San Diego, April 9, 2003.
  • 2003 - Cancer Therapeutics Grand Rounds, “Lung Cancer Prevention with Selenium Supplementation”, RPCI, May 2003.
  • 2003 - Medical and Surgical Fellows Lecture Series, “Chemoprevention: From Mice to Men”, RPCI, 2003.
  • 2005 - Cancer Therapeutics Grand Rounds, “Selenium Supplementation and Vitamin E Status”, RPCI, February 2005.
  • 2005 - Epidemiology Lecture Series, “Research Program in a High Risk Lung Cancer Cohort”, Memorial Sloan Kettering Cancer Center, New York, New York, September 2005.
  • 2005 - University of Chicago, Chicago IL. “Lung Cancer Screening in High Risk Cohort: the Roswell Park Experience 1998 – 2005”. October 2005.
  • 2005 - Roswell Park Cancer Institute, Buffalo NY. Cancer Therapeutics and Prevention Grand Rounds, “Calcitriol and Lung Cancer Prevention”, November 2005.
  • 2006 - Symposium on Quality Health among Older Individuals: What Should We Recommend? “Selenium and Cancer Prevention”, Nutrition and the Center for Healthy Aging, the Obesity Nutrition Research Center (ONRC) and the Department of Epidemiology at the University of Pittsburgh, May 2006.
  • 2007 - Cancer Institute of New Jersey, Prevention Grand Rounds, “Selenium and Cancer”, May 2007.
  • 2007 - Johns Hopkins University, Baltimore, MD “The Prevalence and Persistence of Premalignant Lung Lesions: Findings from a High Risk Cohort”. November 9, 2007.
  • 2008 - Johns Hopkins University, MD, Welch Center for Prevention, Epidemiology and Clinical Research Grand Rounds. “Selenium and Cancer”. March 19, 2008.
  • 2009 - Arizona Cancer Center, Tucson AZ. Cancer Prevention Grand Rounds. “Lung Cancer Screening and Chemoprevention”. February 4, 2009.
  • 2009 - ASPO Career Development Workshop, Tampa, FL. “Approaching applications for funding from multiple agencies”, March 7, 2009.
  • 2009 - Moffitt Cancer Center, Tampa, FL. Medical Grand Rounds. “Lung Cancer Screening and Chemoprevention at Roswell Park”, March 13, 2009.
  • 2009 - University of Pittsburgh Cancer Institute, Pittsburgh, PA. “Lung Cancer Screening and Biomarkers”, April 28, 2009.
  • 2010 - ASPO Career Development Workshop, Bethesda, MD. “Grant Writing: Overviews, Updates and Insights”, March 23, 2010.
  • 2010 - University of California, Los Angeles (UCLA), Los Angeles, CA. “Lung Cancer Surveillance and Chemoprevention”, May 13, 2010.
  • 2010 - Roswell Park Cancer Institute, Buffalo, NY. “Lung Cancer: A Few Facts That You Should Know”, March 24, 2010.
  • 2010 - Buffalo Fire Department, Buffalo, NY. In-Service Education Program, “Lung Cancer: What Fire Fighters Should Know”. 10 firehouse lectures from June- August, 2010.
  • 2010 - Roswell Park Cancer Institute, Buffalo, NY. “Trends in Lung Cancer Epidemiology”. September 25, 2010.
  • 2010 - AACR Frontiers in Prevention Meeting, Philadelphia, PA. “Oral Cancer Screening Using Autofluorescence”. November 10, 2010.
  • 2011 - Providence Hospital, Spokane, WA. “Lung Cancer Screening: the Roswell Park Experience”. March 16, 2011.
  • 2011 - Roswell Park Cancer Institute, Buffalo, NY. Continuing Medical Education for Primary Care Practitioners: Lung Cancer. “Lung Cancer Epidemiology”. March 19, 2011.
  • 2011 - Roswell Park Cancer Institute, Buffalo, NY. Medical Grand Rounds. “Overview of the Results of the National Lung Cancer Screening Trial: Clinical Implications”. September 16, 2011.
  • 2011 - Karmanos Cancer Institute, Detroit MI. Medical Grand Rounds, “Lung Cancer Surveillance”. September 22, 2011.
  • 2011 - James Cancer Center, Ohio State Medical Center, Columbus OH. Cancer Control Program Seminar. “Bimodality Screening for Aerodigestive Cancers”. September 28, 2011.
  • 2011 - Roswell Park Cancer Institute, Buffalo, NY. Nursing Education Series. “Lung Cancer Epidemiology”, September 26, 2011.
International
  • 2002 - London School of Hygiene and Tropical Medicine, “Results of a Clinical Trial of Wheat Bran Fiber”, April 2000.
  • 2002- Schrauzer Symposium, “Selenium and Cancer Prevention”, Baden-Baden, Germany. October 2002.
  • 2004 - University of Surrey Biochemistry Department Lecture Series, “Selenium and Prostate Cancer Chemoprevention”, Guilford, UK, Guilford, UK, July 2004.
  • 2004 - University of Leeds Epidemiology Guest Lecture Series, “Selenium and Cancer Prevention”, Leeds, UK, July 2004.
  • 2005 - Trace Elements in Medicine and Animals, “Vitamin E and Selenium Supplementation: Results from a Clinical Trial”, Coleraine, Ireland, June 2005.
  • 2007 - International Association of Oral Oncology, “Autofluorescence Detection of Oral Malignancies”, Amsterdam, May 2007.
  • 2007 - World Lung Cancer Conference, IASLC. “The Prevalence and Persistence of Premalignant Lung Lesions: Findings from a High Risk Cohort”. Seoul, Korea. September 2, 2007.
  • 2008 - Princess Margaret Hospital, University of Toronto, ON. “The Results of Screening High Risk Lung Cancer Patients with Multiple Modalities: the Roswell Park Experience”. May 6, 2008.
  • 2008 - Selenium: a Multifaceted Element and the Thyroid; a Satellite Meeting of the European Thyroid Association. Hotel Grande Bretagne, Athens, Greece. “Selenium Levels and Cancer Protection: What We have Learned from NPC Studies”. September 19, 2008.
  • 2010 - Frontiers in Carcinogenesis and Cancer Prevention. Reliance Life Sciences Institute, Mumbai, India. Chairperson, Lung Cancer Prevention Session. “Lung Cancer Prevention: Overview of the State of the Art”. February 5-7, 2010.
  • 2010 - Second Niagara Lung Cancer Symposium 2010. Niagara-on-the-Lake, Ontario, Canada. Program Co-Chair. “Choosing the Optimal Populations for Prevention: Defining Risk and Designing Trials”. September 10, 2010.
DECAMP-2: Screening of Patients With Early Stage Lung Cancer or at High Risk for Developing Lung Cancer
Learn More

Clinical Trials

DECAMP-2: Screening of Patients With Early Stage Lung Cancer or at High Risk for Developing Lung Cancer
Learn More
Young Adults, Black Americans Face Increasing Risk of Colorectal Cancer Lung Cancer in Non-Smokers When Am I a Cancer Survivor? For Railroad Workers, Cancer Risk Is All Around How Firefighters Can Reduce Their Cancer Risk New Center Points the Way Toward “Your Best Life” What Veterans Need to Know About Lung Cancer Risk

Featured on Cancer Talk

Young Adults, Black Americans Face Increasing Risk of Colorectal Cancer
Lung Cancer in Non-Smokers
When Am I a Cancer Survivor?

Showing all3 of 7

Publications

Full Publications list on PubMed
  • Bhaskarla A, Tang PC, Mashtare T, Nwogu CE, Demmy TL, Adjei AA, Reid ME, Yendamuri S. Analysis of second primary lung cancers in the SEER database. Journal of surgical research 2010; 162(1):1-6
  • Tang L, Zirpoli GR, Jayaprakash V, Reid ME, McCann SE, Nwogu CE, Zhang Y, Ambrosone CB, Moysich KB. Cruciferous vegetable intake is inversely associated with lung cancer risk among smokers: a case-control study. BMC cancer 2010; 10 :162
  • Mazzilli SA, Reid ME, Foster BA, Johnson CS, Trump DL. The effects of l alpha,25-dihydroxyvitamin D3 (calcitriol) on the tumor-igenesis of lung squamous cell carcinoma. Proceedings of the American Association for Cancer Research Annual Meeting 2010; 51:460
  • Peppone LJ, Reid ME, Moysich KB, Morrow GR, Jean-Pierre P, Mohile SG, Darling TV, Hyland A. The effect of secondhand smoke exposure on the association between active cigarette smoking and colorectal cancer. Cancer causes and control : CCC 2010; 21(8):1247-1255
  • Peppone LJ, Ling MN, Huston AJ, Palesh OG, Mustian KM, Rosier RN, Reid ME, Purnell JQ, Hebl S, Morrow GR. The efficacy of calcitriol therapy in the management of bone loss and fractures: a qualitative review. Osteoporosis international 2010; 21(7):1133-1149
  • Warren GW, Gal T, Martella A, Marshall J, Cummings M, Reid M, Sims J, Valentino J, Arnold S, Kudrimoti M. Weekly self-reported tobacco use and cessation during definitive radiotherapy or chemoradiotherapy for head and neck cancer. International journal of radiation oncology, biology, physics 2010;78(3 Suppl. 1):S563
  • Chadha MK, Rigual NR, Thankappan K, Jayaprakash V, Sullivan M, Reid ME, Loree TR. Induction chemotherapy for stage III/IV oral and oropharyngeal squamous cell cancers. Journal of clinical oncology 2010; 28(15 Suppl.):e16012
  • Vandergrift JL, Pisters K, Niland JC, Otterson GA, Kalemkerian GP, Ettinger DS, Rabin MS, Reid ME, Zornosa C, Mamet R, NCCN Oncology Outcomes Database Non-Small Cell Lung Cancer Disease Specific Executive Committee .First-line systemic therapy in metastatic non-small cell lung cancer (mNSCLC) patients treated at National Comprehensive Cancer Network (NCCN) institutions: An analysis from the NCCN Oncology Outcomes Database Project.Journal of clinical oncology 2010; 28(15 Suppl.):7634
  • Zornosa C, Pisters K, Niland JC, Hayman J, Rabin MS, Otterson GA, Ettinger DS, Reid ME, Mamet R, NCCN Oncology Outcomes Database Non-Small Cell Lung Cancer Disease-Specific Executive Committee. Utilization of adjuvant therapy among completely resected non-small cell lung cancer (NSCLC) patients in the National Comprehensive Cancer Network (NCCN) Outcomes Database Project. Journal of clinical oncology 2010; 28(15 Suppl.):7017
  • Ailawadhi S, Derby L, Natarajan R, Fetterly G, Reid M, Ramnath N. Erlotinib for metastatic non-small-cell lung cancer: first-, second- or third-line setting - does it matter ? A single-institution experience. Oncology 2009; 76(2):85-90
  • Jayaprakash V, Bogaards A, Frustino J, Gill SR, Wilson BC, Mang TS, Hutson AD, Marshall JR, Johnson T, Ramananda S, Moysich KB, Popat SR, Loree TR, Rigual NR, Merzianu M, Sullivan M, Reid ME. Autofluorescence-guided surveillance for oral cancer. Cancer prevention research (Philadelphia, Pa.)2009; 2(11):966-974
  • Peppone LJ, Hyland A, Moysich KB, Reid ME, Piazza KM, Purnell JQ, Mustian KM, Morrow GR. Examining the association between cigarette smoking and colorectal cancer using historical case-control data. Cancer epidemiology2009; 33(3-4):182-188
  • Tezal M, Wactawski-Wende J, Lillis C, Hauck L, Merzianu M, Rigual NR, Loree TR, Reid ME, Stoler D, Marshall JR, Hyland A, Sullivan MA, Scannapieco FA.Chronic periodontitis and the incidence of head and neck squamous cell carcinoma. Cancer epidemiology, biomarkers and prevention 2009;18(9):2406-2412
  • Ferketich AK, Reid ME, Pisters KM, Kalemkerian GP, Ettinger DS, D'Amico TA, Zornosa C, Mamet R, Niland JC, Otterson GA. Survival among smokers and nonsmokers in the National Comprehensive Cancer Network (NCCN) Non-small Cell Lung Cancer (NSCLC) Cohort. Journal of thoracic oncology 2010;5(12 Suppl. 7):S513
  • Mackinnon AC, Reid ME, Husain AN, Krausz T, Joseph L, Yan BC, Mehta RG, Henderson L, Tretiakova M, Salgia R. Paxillin expression and amplification in early lung lesions of high-risk patients, lung adenocarcinoma and metastatic disease. Journal of clinical pathology 2011; 64(1):16-24
  • Peppone LJ, Purnell JQ, Janelsins MC, Mustian KM, Trump DL, Zakharia Y, Rosier RN, Reid ME, Huston AJ, Morrow GR. The effect of various vitamin D supplementation regimens in breast cancer patients. Breast cancer research and treatment 2011; 127(1):171-177
  • Jayaprakash V, Natarajan KK, Moysich KB, Rigual NR, Ramnath N, Natarajan N, Reid ME. Wood dust exposure and the risk of upper aero-digestive and respiratory cancers in males. Occupational and environmental medicine 2008;65(10):647-654
  • Pande R, Sunga A, Levea C, Wilding GE, Bshara W, Reid M, Fakih MG.Significance of signet-ring cells in patients with colorectal cancer. Diseases of the colon and rectum 2008; 51(1):50-55
  • Peppone LJ, Mahoney MC, Cummings KM, Michalek AM, Reid ME, Moysich KB, Hyland A. Colorectal cancer occurs earlier in those exposed to tobacco smoke: implications for screening. Journal of cancer research and clinical oncology 2008; 134(7):743-751
  • Reid ME, Clark LC, Alberts DS, Combs GF Jr, Jacobs E, Turnbull B, Natarajan N, Slate E, Duffield-Lillico AJ, Marshall JR. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and cancer 2008; 60(2):155-163
  • Reid ME, Santella R, Ambrosone CB. Molecular epidemiology to better predict lung cancer risk. Clinical lung cancer 2008; 9(3):149-153
  • Frankel PH, Reid ME, Marshall JR. A permutation test for a weighted Kaplan-Meier estimator with application to the nutritional prevention of cancer trial.Contemporary clinical trials 2007; 28(4):343-347
  • Kuehnelt D, Juresa D, Francesconi KA, Fakih M, Reid ME. Selenium metabolites in urine of cancer patients receiving L-selenomethionine at high doses. Toxicology and applied pharmacology 2007; 220(2):211-215
  • Loewen G, Natarajan N, Tan D, Nava E, Klippenstein D, Mahoney M, Cummings M, Reid M. Autofluorescence bronchoscopy for lung cancer surveillance based on risk assessment. Thorax 2007; 62(4):335-340
  • Nowak NJ, Hicks D, Weiss LM, Sullivan M, Rigual N, Loree T, Stoler D, Reid M, Mhawech-Fauceglia P, Forman SJ, Kernstine K, Smith DD, Bobadilla D, Gaile D, Moore SR, Miecznikowski J, Slovak ML. Challenges in array comparative genomic hybridization for the analysis of cancer samples. Genetics in medicine2007; 9(9):585-595
  • Ramnath N, Demmy TL, Antun A, Natarajan N, Nwogu CE, Loewen GM, Reid ME. Pneumonectomy for bronchogenic carcinoma: analysis of factors predicting survival. Annals of thoracic surgery 2007; 83(5):1831-1836
  • Ramnath N, Menezes RJ, Loewen G, Dua P, Eid F, Alkhaddo J, Paganelli G, Natarajan N, Reid ME. Hormone replacement therapy as a risk factor for non-small cell lung cancer: results of a case-control study. Oncology 2007; 73(5-6):305-310
  • Stranges S, Marshall JR, Natarajan R, Donahue RP, Trevisan M, Combs GF, Cappuccio FP, Ceriello A, Reid ME. Effects of long-term selenium supplementation on the incidence of type 2 diabetes: a randomized trial.Annals of internal medicine 2007; 147(4):217-223
  • Faoro L, Krausz T, Armato SG 3rd, Reid ME, Cheney RT, Ferguson MK, El-Zayaty SA, Salgia R, Hutto JY, Husain AN. Lymphatic vessel density is not associated with lymph node metastasis in non-small cell lung carcinoma.Archives of pathology and laboratory medicine 2008; 132(12):1882-1888
  • Menezes RJ, Salgia R, Moysich KB, Jayaprakash V, Johnson CS, Loewen G, Tretiakova M, Husain A, Cheney RT, Reid ME. Vitamin D receptor expression in normal, premalignant, and malignant human lung tissue. Cancer epidemiology, biomarkers and prevention 2008; 17(5):1104-1110
  • Tezal M, Wactawski-Wende J, Hauck L, Lillis C, Loree T, Hyland A, Marshall JR, Reid ME, Sullivan MA, Scannapieco FA. Chronic periodontitis and the risk of tongue cancer. Archives of otolaryngology--head and neck surgery 2007;133(5):450-454
  • Jayaprakash V, Cheng C, Reid M, Dexter EU, Nwogu CE, Hicks W, Sullivan M, Demmy TL, Yendamuri S. Previous head and neck cancers portend poor prognoses in lung cancer patients. Annals of thoracic surgery 2011;92(3):1056-1061
  • Mazzilli SA, Reid ME, Foster BA, Trump DL, Johnson CS. The effects of vitamin D on the tumorigenesis of lung squamous cell carcinoma in a carcinogen incduced mouse model. Journal of thoracic oncology 2011; 6(6 Suppl. 2):S939-S940
  • Bickel KE, Niland JC, Mamet R, Zornosa CC, Ettinger DS, Pisters K, Otterson GA, Koczywas M, Reid ME, Rabin MS, D'Amico TA, Earle C, Pini TM, Kalemkerian GP. Aggressive end-of-life (EOL) chemotherapy (CT) use in metastatic non-small cell lung cancer (mNSCLC): A National Comprehensive Cancer Network (NCCN) outcomes database analysis : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):7537
  • Cummings KM, Hyland A, Zevon M, Kelly M, Long MA, Demmy TL, Dexter E, Reed R, Epstein J, Houston T, Jenkins D, Mahoney M, O'Connor R, Marshall JR, Reid ME, Smith JL, Chmura M, Warren GW. An institutional universal standardized tobacco use assessment and intervention in cancer patients : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):e16543
  • Warren GW, Kasza K, Reid ME, Cummings KM, Marshall JR. Prospective structured smoking behavior assessment at diagnosis and long-term cancer survival : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011;29(15 Suppl.):1557
  • Feser WJ, Baron AE, Wolf HJ, Jayaprakash V, Reid M, Keith RL, Kennedy TC, Hirsch FR, Franklin WA, Miller YE, Byers T. Analysis of bronchial histology and incident lung cancer - a prospective approach. Journal of thoracic oncology2009; 4(9 Suppl. 1):S490-S491
  • Franklin WA, Crichton D, Reid M, Mattmann C, Hart A, Deng D, Chesnut P, Logue B, Stelling D, Varella-Garcia M, Kennedy TC, Miller YE. A distributed bronchial mapping software tool for the tracking of cellular, molecular and imaging results in the central airways. Journal of thoracic oncology 2009; 4(9 Suppl. 1):S339
  • Ghadersohi A, Bogner PN, Fayazi Z, Demmy TL, Reid M, Wilding G, Reska N, Slocum H, Groth J, Azrak RG, Rustum YM, Li F. Downregulation of PDEF expression in lung carcinoma is associated with up regulation of survivin and malignant potential. Proceedings of the American Association for Cancer Research Annual Meeting 2007; 48:797
  • Mackinnon A, Tretiakova M, Manaligod J, Krausz T, Husain A, Cheney R, Reid M, Salgia R. Paxillin in non-small cell lung cancer (NSCLC) development and progression: immunohistochemical, molecular, and epidemiological analysis of transbronchial biopsies from high-risk patients. Histopathology 2008; 53:813
  • Mang T, Sullivan-Nasca M, Reid M, Rigual N, Jayaprakash V, Menezes R, Loree T. Autofluorescence detection of oral malignancies. Oral oncology 2007;2(Suppl.):121
  • Reid ME, Jayaprakash V, Menezes R, Natarajan R, Loewen G. The prevalence and persistence of premalignant lesions: a report of a high risk lung cancer cohort. Journal of thoracic oncology 2007; 2(8 Suppl.):S331-S332
  • Santella RM, Zhang YJ, Wang Q, Redman M, Chansky K, Reid M, Davis W, Gandara D, Powell CA, Albain K, Ambrosone C. Biomarkers of polycyclic aromatic hydrocarbon-DNA damage and cigarette smoke exposure. Journal of thoracic oncology 2009; 4(9 Suppl. 1):S164
  • Stranges S, Marshall JR, Natarajan R, Donahue RP, Trevisan M, Cappuccio FP, Combs GF, Clark LC, Reid ME. Effects of selenium supplementation on type 2 diabetes incidence: Secondary analyses in a randomized clinical trial.Circulation 2007; 115(8):E226
  • Sunga AY, Levea C, Fakih M, Reid M, Mahoney M, Smith J, Trump D, Johnson C, Schiff M. Aberrant crypt foci characterization in selected colorectal cancer risk groups. Proceedings of the American Association for Cancer Research Annual Meeting 2007; 48:397
  • Jayaprakash V, Reid M, Hatton E, Merzianu M, Rigual N, Marshall J, Gill S, Frustino J, Wilding G, Loree T, Popat S, Sullivan M. Human papillomavirus types 16 and 18 in epithelial dysplasia of oral cavity and oropharynx: a meta-analysis, 1985-2010. Oral oncology 2011; 47(11):1048-1054
  • Platek ME, Reid ME, Wilding GE, Jaggernauth W, Rigual NR, Hicks WL Jr, Popat SR, Warren GW, Sullivan M, Thorstad WL, Khan MK, Loree TR, Singh AK. Pretreatment nutritional status and locoregional failure of patients with head and neck cancer undergoing definitive concurrent chemoradiation therapy. Head and neck 2011; 33(11):1561-1568
  • Lepisto EM, Vandergrift JL, Kalemkerian GP, Pisters KM, Zornosa C, Rabin MS, Reid ME, Koczywas M, Otterson GA, Ettinger DS. Oncology Medication Utilization Based On Federal Drug Administration (FDA) Labeling, National Comprehensive Cancer Network (NCCN) Clinical Practice Guideline (GL) Recommendations, and Evidence for Patients with Advanced Non Small Cell Lung Cancer (NSCLC): An Analysis From the NCCN Oncology Outcomes Database. Value in health 2011; 14(3):A176-A177
  • Wood DE, Eapen GA, Ettinger DS, Hou L, Jackman D, Kazerooni E, Klippenstein D, Lackner RP, Leard L, Leung ANC, Massion PP, Meyers BF, Munden RF, Otterson GA, Peairs K, Pipavath S, Pratt-Pozo C, Reddy C, Reid ME, Rotter AJ, Schabath MB, Sequist LV, Tong BC, Travis WD, Unger M, Yang SC. Lung cancer screening. Journal of the National Comprehensive Cancer Network : JNCCN 2012; 10(2):240-265
  • Hennon MW, Hylander B, Morrison C, Miller A, Groman A, Dexter E, Yendamuri S, Demmy TL, Adjei A, Reid M, Repasky E, Nwogu C. Predicting NSCLC outcomes based on tumor growth in SCID mice. Proceedings of the American Association for Cancer Research Annual Meeting 2011; 52:Abstract #1610
  • Nwogu CE, Groman A, Fahey D, Yendamuri S, Dexter E, Demmy TL, Miller A,Reid M. Number of lymph nodes and metastatic lymph node ratio are associated with survival in lung cancer. Annals of thoracic surgery 2012;93(5):1614-1619; discussion 1619-1620
  • Reid M, Yasko J. The role of biomarkers in cancer clinical trials. Seminars in oncology nursing 2012; 28(2):116-121
  • Bole C, Jayaprakash V, Platek M, Reid ME, Sullivan M, Loree T, Rigual N, Popat S, Moysich KB. Coffee and tea consumption and risk of head and neck cancers. American journal of epidemiology 2009; 169(Suppl. 11):S49
  • Yendamuri S, Caty L, Pine M, Adem S, Bogner P, Miller A, Demmy TL, Groman A, Reid M. Outcomes of sarcomatoid carcinoma of the lung: A Surveillance, Epidemiology, and End Results database analysis. Surgery 2012;152(3):397-402
  • Zornosa C, Vandergrift JL, Kalemkerian GP, Ettinger DS, Rabin MS, Reid M, Otterson GA, Koczywas M, D'Amico TA, Niland JC, Mamet R, Pisters KM. First-line systemic therapy practice patterns and concordance with NCCN guidelines for patients diagnosed with metastatic NSCLC treated at NCCN institutions.Journal of the National Comprehensive Cancer Network : JNCCN 2012;10(7):847-856
  • Mazzilli SA, Reid ME, Seshadri M, Bogner PN, Foster BA, Johnson CS, Trump DL. Antitumor effects of vitamin D in a carcinogen-induced mouse model of lung cancer. Proceedings of the American Association for Cancer Research Annual Meeting 2012; 53:Abstract #1606

Request an Appointment

Make an appointment by calling 1-800-ROSWELL (1-800-767-9355)

Make an Appointment